Schonfeld Strategic Advisors’s ProKidney PROK Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58.8K	Buy	+32,845	New	+$69.7K	﹤0.01%	1948
2024 Q3	–	Sell	-11,800	Closed	-$29K	–	2346
2024 Q2	$29K	Buy	+11,800	New	+$31.7K	﹤0.01%	1982
2022 Q3	–	Sell	-42,852	Closed	-$426K	–	3122
2022 Q2	$426K	Hold	42,852	–	–	﹤0.01%	1451
2022 Q1	$424K	Buy	+42,852	New	+$423K	﹤0.01%	1473
2021 Q4	–	Sell	-400,000	Closed	-$3.92M	–	2452
2021 Q3	$3.92M	Hold	400,000	–	–	0.04%	506
2021 Q2	$4.04M	Buy	+400,000	New	+$4.04M	0.04%	519

Other funds holding PROK

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

AGP

Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Schonfeld Strategic Advisors's PROK Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in ProKidney (PROK) in Q1 2026: 32,845 shares worth $58.8K. The stake represents ﹤0.01% of the portfolio and ranks #1948 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in PROK as recently as Q2 2024.

Schonfeld Strategic Advisors first reported a position in PROK in Q2 2021 and has held it in 6 quarters since. The position peaked at $4.04M in Q2 2021. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

Schonfeld Strategic Advisors held 32,845 shares of ProKidney worth $58.8K as of Q1 2026.
ProKidney was a new Schonfeld Strategic Advisors position in Q1 2026.
ProKidney made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1948 holding.
Schonfeld Strategic Advisors first reported a position in ProKidney in Q2 2021 and has held it in 6 quarters since.
Schonfeld Strategic Advisors's ProKidney position peaked at $4.04M in Q2 2021.
71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.